MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00259-026-07813-6

Медицинская библиотека · European journal of nuclear medicine and molecular imaging · 2026

[68Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma.

Chen Jie, Tang Shuaihu, Liu Li, Tian Yueli, Wang Yichun, Xiao Zhiwei, Xing Diankui, Zhou Fuling, Li Chongjiao, He Yong

Clinical StudyСтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: This study aimed to assess and compare the Durie-Salmon PLUS staging performance and high-risk prediction capabilities between [68Ga]Ga-Pentixafor and [18F]FDG PET/CT in newly diagnosed multiple myeloma (NDMM).

METHODS

Eligible participants with NDMM who underwent [68Ga]Ga-Pentixafor and [18F]FDG PET/CT between October 2021 and March 2025 were prospectively enrolled in this study (NCT05255926). The diagnostic and staging performance of [68Ga]Ga-Pentixafor and [18F]FDG were assessed and compared. The parameters including standardized uptake value (SUV), tumor-to-liver ratio (TLR), total bone marrow uptake (TBMU), total bone marrow uptake volume (TBMV), and total burden score (TBS) were calculated. Independent predictors for high-risk NDMM were identified using single-factor and multivariate logistic regression.

RESULTS

Sixty-nine participants (40 men) with a median age of 64 years (interquartile range [IQR], 57–71.5 years) were finally analysed. [68Ga]Ga-Pentixafor PET/CT exhibited a higher positive detection rate (82.6% [57/69] vs. 53.6% [37/69], P < 0.001), maximum SUV (SUVmax; 13.5 vs. 5.3 P < 0.001), mean SUV (SUVmean; 3.5 vs. 2.9, P = 0.029), TLR (8.1 vs. 2.0, P < 0.001), and TBS (45 vs. 4, P < 0.001) than [18F]FDG. [68Ga]Ga-Pentixafor-derived TBSCXCR4, TBMVCXCR4, and TBMUCXCR4 positively correlated with bone marrow plasma cell percentage, β2-microglobulin, and total additive score, respectively. For Durie-Salmon PLUS staging, [68Ga]Ga-Pentixafor better identified advanced participants than did [18F]FDG PET/CT (53 vs. 35; P < 0.001). According to the Mayo mSMART 4.0 stratification system, multivariate logistic regression analysis demonstrated that SUVmeanCXCR4 (odds ratio [OR] = 1.752, 95% confidence interval [CI] = 1.085– 2.828, P = 0.022) and TBSCXCR4 (OR = 1.041, 95% CI = 1.011–1.072, P = 0.008) were independent indicators for predicting high-risk NDMM.

CONCLUSION

In NDMM, [68Ga]Ga-Pentixafor demonstrated better diagnostic accuracy, Durie-Salmon PLUS staging, and high-risk prediction capabilities than did [18F]FDG PET/CT. [68Ga]Ga-Pentixafor-derived SUVmeanCXCR4 and TBSCXCR4 could accurately identify high-risk NDMM. Trial registration number: NCT05255926.

Для цитирования: Chen Jie, Tang Shuaihu, Liu Li, Tian Yueli, Wang Yichun, Xiao Zhiwei, Xing Diankui, Zhou Fuling, Li Chongjiao, He Yong. [68Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma.. European journal of nuclear medicine and molecular imaging. 2026. DOI: 10.1007/s00259-026-07813-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.